Neoadjuvant Chemo Did Not Improve Disease-Free Survival - Takeaways - MDSpire
From the Journals

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches

  • By

  • Andrea Surnit

  • May 1, 2026

  • 5 min

Share

  • 1

    NeoCol trial compared neoadjuvant chemotherapy with upfront surgery.

  • 2

    250 patients staged via CT participated from 2013 to

  • 3

    No significant difference in disease-free survival at 3 years (87% vs 83%).

  • 4

    Neoadjuvant chemotherapy showed feasibility with some pathologic downstaging.

  • 5

    Limitations included lower event numbers and modest CT accuracy.

  • 6

    Future studies should evaluate biomarkers for better patient selection.

  • 7

    Investigators noted no other significant findings affecting clinical outcomes.

Original Source(s)

Neoadjuvant Chemo Did Not Improve Disease-Free Survival

  • by Andrea Surnit

  • May 1, 2026

Related Content

Inflammation Tied to Organ Failure Risk

Review outlines mechanisms, prognosis, and supportive care strategies in surgical and trauma ICU populations

Early Enteral Feeding Tied to Fewer Complications

Benefit driven by fewer infections and pulmonary events, though overall complication rates were similar

AI in Surgery: Debate Highlights Benefits, Gaps

Surgeons and researchers clash over whether current AI systems are ready for clinical use — and what responsible adoption would require.